TAKHZYRO (lanadelumab-flyo) (Lanadelumab SOLUTION) 150 mg/mL

TAKHZYRO (lanadelumab) is an FDA-approved orphan drug developed by Takeda Pharmaceuticals for the treatment of hereditary angioedema (HAE). It represents a significant therapeutic advance in the Allergy & Immunology category, offering patients a novel approach to managing this rare genetic disorder through subcutaneous administration.

Strength

150 mg/mL

Pack Size

1 SYRINGE, GLASS in 1 CARTON (47783-645-01) / 1 mL in 1 SYRINGE, GLASS

Manufacturer / TM Owner

Takeda Pharmaceuticals U.S.A., Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TAKHZYRO is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adolescent and adult patients. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling affecting the skin, gastrointestinal tract, and potentially life-threatening airway involvement. TAKHZYRO targets plasma kallikrein, a key enzyme in the contact system pathway responsible for bradykinin production, which drives angioedema formation. By inhibiting plasma kallikrein, lanadelumab reduces the frequency and severity of HAE attacks. The drug is administered as a subcutaneous injection and is designed for patients with HAE Type I, Type II, and Type III (normal C1-INH). Clinical trials demonstrated significant reductions in attack frequency compared to placebo, making it a valuable preventive option for this debilitating orphan disease affecting approximately 1 in 10,000 to 1 in 50,000 individuals.

Side Effects

Common side effects of TAKHZYRO include injection site reactions such as erythema, bruising, and discomfort. Serious adverse events are rare but may include hypersensitivity reactions and thrombotic events. Patients should be monitored for signs of infection, as lanadelumab may affect immune function. Regular clinical assessments are recommended to evaluate treatment efficacy and tolerability. Laboratory monitoring may include coagulation parameters in patients with risk factors for thrombosis. Most adverse events are mild to moderate and manageable with standard supportive care. Patients should report any unusual symptoms, severe reactions, or changes in HAE attack patterns to their healthcare provider.

Precautions & Warnings

TAKHZYRO is contraindicated in patients with known hypersensitivity to lanadelumab or any excipient. Use with caution in patients with thrombotic risk factors or active thrombotic disease. Safety in pregnancy has not been established; use only if benefits outweigh risks. Pediatric use is approved for adolescents; efficacy and safety in children under 12 years require further evaluation. No dose adjustment is necessary for renal or hepatic impairment, though caution is advised in severe hepatic disease. Patients should be counseled on proper subcutaneous injection technique and storage requirements. Live vaccines should be administered with consideration of immunosuppressive effects.

Avoid Interactions

No significant drug-drug interactions have been identified with TAKHZYRO. However, concurrent use with other plasma kallikrein inhibitors or contact system modulators should be avoided due to potential additive effects. Patients taking anticoagulants or antiplatelet agents should inform their healthcare provider, as lanadelumab may have minor effects on coagulation. No specific food interactions are documented. Herbal supplements affecting coagulation should be used cautiously. Always inform healthcare providers of all medications and supplements before initiating TAKHZYRO therapy.

Frequently Asked Questions

TAKHZYRO is used to prevent hereditary angioedema (HAE) attacks in adolescents and adults. It works by inhibiting plasma kallikrein, an enzyme involved in the formation of angioedema. By reducing this enzyme's activity, TAKHZYRO significantly decreases the frequency and severity of HAE attacks.

TAKHZYRO is administered as a subcutaneous injection. Patients typically receive injections every two or four weeks, depending on their response and the dosing schedule prescribed by their healthcare provider. Patients can be trained to self-administer injections at home.

Common side effects include injection site reactions such as redness, bruising, and mild discomfort at the injection site. Most side effects are mild to moderate and resolve without intervention. Serious adverse events are uncommon but should be reported to a healthcare provider immediately.

TAKHZYRO is manufactured by Takeda Pharmaceuticals U.S.A., Inc., a leading global pharmaceutical company specializing in rare diseases and specialty therapeutics.

Yes, TAKHZYRO received FDA orphan drug designation for the treatment of hereditary angioedema. This designation recognizes its importance in treating a rare disease affecting a small patient population. Orphan drug status provides regulatory incentives and support for development of therapies for rare conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.